ALLO.US Allogene Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.8387 USD
Close of Nov 13, 2026
0.8201 4.46
Market cap
USD 291M
P/E
-
P/B
0.73x
ROE
-46.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ALLO.US undervalued?

Graham number

The Graham number of Allogene Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Allogene Therapeutics Inc fundamental analysis

No fundamental analysis for Allogene Therapeutics Inc yet.

Allogene Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engine…

Full company profile